Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) have been given an average rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $55.80.

Several research analysts have recently issued reports on PTHS shares. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Pelthos Therapeutics in a research note on Thursday, March 19th. Zacks Research upgraded Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 24th. Cantor Fitzgerald started coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 price target for the company. Finally, Oppenheimer upped their price target on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Friday, May 15th.

Pelthos Therapeutics Stock Performance

PTHS stock opened at $26.71 on Friday. The company has a quick ratio of 1.86, a current ratio of 2.79 and a debt-to-equity ratio of 1.41. The firm’s 50 day simple moving average is $27.00. Pelthos Therapeutics has a 52-week low of $16.50 and a 52-week high of $37.50. The stock has a market capitalization of $92.95 million, a price-to-earnings ratio of -1.29 and a beta of 3.10.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share for the quarter. The company had revenue of $10.91 million during the quarter. As a group, sell-side analysts forecast that Pelthos Therapeutics will post -12.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pelthos Therapeutics news, Director Todd C. Davis bought 35,948 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $27.82 per share, with a total value of $1,000,073.36. Following the transaction, the director owned 75,834 shares in the company, valued at $2,109,701.88. This represents a 90.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 1,638 shares of company stock valued at $43,107. 12.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Knott David M Jr raised its stake in Pelthos Therapeutics by 9.3% during the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock valued at $443,000 after buying an additional 1,792 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Pelthos Therapeutics by 31.9% in the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after acquiring an additional 3,295 shares during the period. Persistent Asset Partners Ltd increased its position in Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after acquiring an additional 3,604 shares during the last quarter. Pale Fire Capital SE increased its position in Pelthos Therapeutics by 59.5% during the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after acquiring an additional 4,819 shares during the last quarter. Finally, Millennium Management LLC bought a new position in Pelthos Therapeutics in the fourth quarter valued at about $343,000. Institutional investors own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).